Drug – bio-affecting and body treating compositions – Live hair or scalp treating compositions – Astringent or sebum inhibiting
Reexamination Certificate
2001-01-26
2003-02-04
Page, Thurman K. (Department: 1615)
Drug, bio-affecting and body treating compositions
Live hair or scalp treating compositions
Astringent or sebum inhibiting
C424S070100
Reexamination Certificate
active
06514490
ABSTRACT:
The invention relates to compositions such as body and hair cleansing products, in particular shampoos, comprising one or more antifungals inhibiting fungal ergosterol biosynthesis as a first active ingredient, 10′-undecen-3-oyl-aminopropyl trimethyl-ammonium methylsulfate as a second active ingredient and as a cationic surface active agent, and art-known body or hair cleansing product ingredients as a carrier.
BACKGROUND OF THE INVENTION
Known medicated shampoos are, for example, the ketoconazole shampoos which are marketed in a 2% formulation and which show a beneficial effect in dandruff and seborrheic dermatitis after topical application. Ketoconazole was disclosed by Rosenberg et al. in U.S. Pat. No. 4,569,935 to be useful in the topical treatment of psoriasis and seborrheic dermatitis. Ketoconazole shampoos that exhibit better cosmetic attributes such as lathering and conditioning, and are acceptably stable to degradation so that they can be formulated to contain less than 2% active ingredient are disclosed in U.S. Pat. No. 5,456,851. Elubiol shampoos having a skin grease regulating action are known from WO-93/18743. WO-96/29983 discloses mild aqueous detergent compositions comprising from about 4 to about 12% by weight of an anionic surfactant, an amphoteric surfactant at a level of at least about 0.75 parts by weight per part by weight of said anionic surfactant, and one or more of 11 listed therapeutic agents. 10′-Undecen-3-oyl-aminopropyl trimethylammonium methylsulfate is a cationic surfactant commercially available under the Trademark Rewocid UTM 185, marketed by Rewo Chemische Werke GmbH, Steinau (Germany) and by Witco.
Prior art shampoos comprising anti-dandruff agents are designed in such a way that an optimum balance is achieved between efficacy and tolerability; the concentration of the active ingredient in the medicated shampoos is such that as many users as possible are effectively treated and as few as possible suffer adverse effects. Nonetheless, there remain substantial numbers of patients who do not benefit from using prior art shampoos, either because they do not respond to the treatment, or worse, because they do not tolerate the treatment with a particular medicated shampoo.
The number of patients not responding to particular medicated shampoo can be quite high (ketoconazole up to 30%; selenium sulfide up to 40%). Consequently, there is a hard felt need for new shampoos which provide effective anti-dandruff treatment for a larger proportion of number of patients using such a new shampoo; i.e. a new shampoo for which there are fewer non-respondents than with prior art shampoos.
On the other hand, patients suffering from dandruff or seborrheic dermatitis, as well as the authorities approving medicated shampoos, apply increasingly stricter criteria which such shampoos should meet. Amongst these criteria the most important are: absence of further aggravation of the condition due to the treatment, lowest possible incidence of side effects, further increase in the absence of symptoms such as irritation, pruritus and scaling (both adherent and loose scaling); improved cosmetic acceptability, in particular, good cleansing properties, absence of odour or stench, absence of staining or soiling of the clothes, and overall conditioning (wet and dry combing properties). Dandruff or seborrheic dermatitis are often accompanied by high or excessive oil or sebum production, and compositions having a beneficial effect thereon would clearly constitute a further advance in the treatment of dandruff.
Thus far, in order to achieve the above desiderata, most efforts have involved reformulating the shampoo base. There is, however, still a need for increasing the tolerability/acceptability of medicated shampoos, i.e. new shampoos are desired that are tolerated better by larger proportions of patients using such new shampoos.
DESCRIPTION OF THE INVENTION
The present invention relates to compositions such as body and hair cleansing products, in particular shampoos, comprising, consisting essentially of or consisting of one or more antifungals inhibiting fungal ergosterol biosynthesis as a first active ingredient, 10′-undecen-3-oyl-aminopropyl trimethylammonium methylsulfate as a second active ingredient, and art-known body and hair cleansing product ingredients as a carrier. In the following description, the invention is illustrated using shampoos as examples, but it will be evident to a person skilled in the art that the combinations according to the present invention can be utilized just as well in other body and hair cleansing products.
The combination of two differently acting anti-dandruff agents has two distinct advantages over the prior art shampoos which contain either of the active ingredients alone. First, the combinations act synergistically and as a consequence thereof, the concentration of one or both of the different types of agent can be lowered, thus increasing the tolerability. Secondly, an increased proportion of patients suffering from dandruff or seborrheic dermatitis respond to the shampoos according to the present invention. Each class of ingredients will now be discussed in turn.
The antifungal inhibiting fungal ergosterol biosynthesis is preferably an azole, an allylamine, or a mixture thereof. Preferred azoles are selected from the group comprising ketoconazole, econazole, elubiol, miconazole, itraconazole, fluconazole and mixtures thereof. Preferred allylamines are selected from the group comprising terbinafine, naftifine and mixtures thereof. The azole compounds ketoconazole, econazole and elubiol are most preferred because they harm the normal flora of the skin, in particular of the scalp, the least. Ketoconazole and elubiol are especially preferred as they produce a mutual synergistic effect on dermatophyte fungi when in used in combination with 10′-undecen-3 -oyl-aminopropyl trimethylammonium methylsulfate (vide infra). Effective amounts of the antifungals in compositions according to the present invention are in the range of from about 0.1% to about 2.5% (w/w), and preferably from about 0.5% to about 1% (w/w). As will be explained further, at the lower end of this range, special precautions may have to be taken in order to ensure that the shampoo does not lose its efficacy due to degradation of the antifungal compound upon storage. Concentrations higher than those indicated do not improve the treatment of the conditions any further, and are on the whole more detrimental than beneficial.
The second active ingredient is 10′-undecen-3-oyl-aminopropyl trimethylammonium methylsulfate having the formula
Its Chemical Abstracts registry number is [94313-91-4], its CTFA Adopted Name is Undecylenamidopropyltrimonium Methosulfate. This cationic surfactant is commercially available under the Trademark Rewocid UTM 185, marketed by Rewo Chemische Werke GmbH, Steinau (Germany) and by Witco. The commercial product is an aqueous formulation having a solids content in the range of 47 to 49%, appearing as a clear yellow liquid and giving a pH in the range of 5 to 7 when diluted to 1% in water.
Preferably, the first and the second active ingredients are present in quantities producing a mutual synergistic effect on the inhibition of the growth of dermatophyte fungi, in particular the species associated with dandruff and seborrheic dermatitis, i.e.
Malassezia furfur
(
Pityrosporum ovale
), but also other fungi such as Epidermophyton, Microsporum, Trichophyton species associated with, for example, dermatophytosis, pityriasis versicolor and the like. The ratio of the quantities of the first and the second active ingredient will depend on the nature of said active ingredients and on the target species. Particularly, it is contemplated that the weight:weight ratio between the first and the second active ingredient (antifungal: 10′-undecen-3-oyl-aminopropyl trimethylammonium methylsulfate) may range from about 5:1 to about 1:150, in particular from about 1:1 to about 1:25. For example, and as already mentioned, ketoconazole
De Doncker Piet Richard Gudula
Embrechts Roger Carolus Augusta
Odds Frank Christopher
Janssen Pharmaceutica N.V.
Page Thurman K.
Ware Todd D
LandOfFree
Compositions containing an antifungal and a cationic agent does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions containing an antifungal and a cationic agent, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions containing an antifungal and a cationic agent will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3144679